Simcere Seeks Oncology Acquisitions, Ex-China Licensing Partners For Endu
This article was originally published in PharmAsia News
Executive Summary
Simcere Pharmaceutical Group plans to be one of the last China-based pharmaceutical firms standing after a predicted major consolidation could shrink that industry to as few as 1,000 companies in the next several years